The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Daniel Zheng, MD, a pediatric oncologist at the Children’s Hospital of Philadelphia, and Chiara Bona, MD, a pediatric oncologist at Dana-Farber Boston Children’s Cancer and Blood Disorders Center, discuss their research on financial toxicity in pediatric leukemia.
Var-cel was approved in 2021 in Spain for patients ages 25 years and older with relapsed or refractory B-cell precursor ALL.
Dr. Manson covers the importance of treating the underlying driver of HLH to prevent recurrence and improve patient outcomes. She also highlights resources like the “Getting It Right First Time” (GURFT) guidelines and the Hi-HASK collaboration.
Prof. Amanda Goodall, director of the Executive Master’s in Medical Leadership (EMML), a specialized MSc degree from Bayes Business School offering advanced leadership training to medical doctors, joined SOHO Insider podcast host Prof. Christopher Fox, a professor of hematology at Nottingham University Hospitals NHS Trust, for a discussion on leadership in healthcare.
The approval is based on the phase 3 BRUIN CLL-321 trial, the first randomized study in patients pre-treated with a covalent BTK inhibitor. Pirtobrutinib monotherapy significantly prolonged progression-free survival versus investigator’s choice (idelalisib + rituximab or bendamustine + rituximab), with lower discontinuation due to treatment-related adverse events
To access the SOHO Career Center click the following link.
